Latest:
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
By Marianne Davies, RN, MSN, ACNP, AOCNP
Latest:
Journal Club Bridges Research and Practice, Improving Patient Care
Three oncology nurses at the Smilow Cancer Hospital at Yale-New Haven write about the Smilow Society, an interactive and innovative journal club enabling nurses to stay abreast of important research developments, which can then be translated directly into clinical practice.
By Marissa Howard-McNatt, MD
Latest:
BRCA Testing and Contralateral Prophylactic Mastectomy
Determination of BRCA1 and 2 mutation carrier status has become increasingly important. Estimates suggest that about 80% of breast cancers and 90% of ovarian cancers are sporadic; while only 5% to 10% of breast cancers are hereditary.
By Mary K. Caffrey
Latest:
Pomalidomide Shows Benefits in Trials Testing New Combinations
Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.
By Michael M. Mohundro, PharmD
Latest:
The Future of Melanoma Treatment
Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.
By Paul M. Zeltzer, MD
Latest:
From Pronouncement to Partnership: Understanding New Modes of Communication in a Changing Healthcare System
The dramatic change in healthcare delivery from private practitioner-based to managed care created a vacuum of responsibility for self care that the patient has needed to fill.
By Peter Ciszewski
Latest:
Trial for Anti-Lung Cancer Compound ASA404 Progresses to Phase III
A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis' novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC). NSCLC is the most prevalent cause of cancer death among men and women in the United States and globally.